Home » CSMC GRANTS RIGHTS OVER RIFAXIMIN TO SALIX
CSMC GRANTS RIGHTS OVER RIFAXIMIN TO SALIX
Salix Pharmaceuticals, Ltd. announced that the company has entered into an agreement with Cedars-Sinai Medical Center, (CSMC), for the right to use US Patent No. 6,861,053 and US Patent Application No. 11/234,516 relating to methods of diagnosis and treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth. ()A HREF="http://pharmabiz.com/article/detnews.asp?articleid=34142" TARGET="_blank">PharmaBiz
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May